Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after ...

Three Senate Democrats called for an investigation into the developers of brain-computer interface devices, including ...

Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

In February, the HHS unexpectedly delivered notice that the South San Francisco-based company was to stop all work on the ...

Ferrer’s R&D work focuses on neurological and pulmonary diseases, and the Spanish pharma has bought into ALS assets in the ...

The former head of Johnson & Johnson’s worldwide medtech business, Ashley McEvoy, has signed up to lead the insulin ...

Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. | Novartis has ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

The CEO of Novo Holdings has warned that his $160 billion fund will slow down investment activity until the dust settles ...

Medtronic confirmed that its Hugo surgical robot system has been submitted to the FDA for review, alongside the successful completion of a large clinical trial evaluating its performance | According ...